Everolimus
Approved · FDA / EMAAlso known as Afinitor, Torpenz, Zortress, 40-O-(2-hydroxyethyl)-rapamycin+2 more
Afinitor, Torpenz, Zortress, 40-O-(2-hydroxyethyl)-rapamycin, 42-O-(2-Hydroxyethyl)rapamycin, évérolimus.
Recent clinical, regulatory, research and industry developments relating to this drug.
Approval: EVEROLIMUS (ANDA219464)
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.
Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous… Show full indicationShow less
Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery. The evidence is based on analysis of change in sum of angiomyolipoma volume. Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) Votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery. The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease?related symptoms, has not been demonstrated.
Indication: Hormone-receptor-positive advanced breast cancer Afinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination… Show full indicationShow less
Hormone-receptor-positive advanced breast cancer Afinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. Neuroendocrine tumours of pancreatic origin Afinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease. Neuroendocrine tumours of gastrointestinal or lung origin Afinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. Renal-cell carcinoma Afinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine4
- Cancer3
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology2
- American journal of hematology1
- Annals of neurology1
- Cancer chemotherapy and pharmacology1
- Witzig TE4
- Ansell SM3
- Choueiri TK3
- Donskov F3
- Escudier B3
- Habermann TM3
- Johnston PB3
- Larkin J3
- The University of Texas MD Anderson Cancer Center3
- Department of Pathology and Laboratory Medicine2
- Mayo Clinic2
- Mayo Clinic College of Medicine and Mayo Foundation2
- Sidney Kimmel Comprehensive Cancer Center2
- Aarhus University Hospital1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Everolimus, with 6 overlapping disease areas.
Studied across 2 of the same disease areas as Everolimus in the shared literature.
Studied across 2 of the same disease areas as Everolimus in the shared literature.
Studied across the same disease area as Everolimus in the shared literature.
Studied across the same disease area as Everolimus in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.